| [1] |
Öberg KE.Gastrointestinal neuroendocrine tumors.Ann Oncol, 2010, 21(7): 72-80.
|
| [2] |
Warner RR.Enteroendocrine tumors other than carcinoid：a review of clinically significant advances.Gastroenterology, 2005, 128: 1668-1684.
|
| [3] |
Modlin IM,Oberg K,Chung DC, et al.Gastroenteropancreatic neuroendocrinetumours.Lancet Oncol, 2008, 9(1): 61-72.
|
| [4] |
Yao JC.Phan AT, Chang DZ, et al.Efficacy of RADOOl(everolimus)and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors：results of a phase II study.J Clin Oncol, 2008, 1926: 4311-4318.
|
| [5] |
Caldarella A,Crocetti E,Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors：a population based study from a cancer registry.Pathol Oncol Res, 2011, 17: 759-763.
|
| [6] |
Luke C,Price T,Townsend A, et al.Epidemiology of neuroendocrine cancers in an Australian population.Cancer Causes Control, 2010, 21: 931-938.
|
| [7] |
Klimstra,DS,Modlin,IR,Adsay,NV, et al.Pathology reporting of neuroendocrine tumors：application of theDelphic consensus process to the development of a minimumpathology data set.Am J Surg Pathol, 2010, 34: 300-313.
|
| [8] |
Caplin ME,Buscombe JR,Hilson AJ, et al.Carcinoid tumour.Lancet, 1998, 352(9130): 799-805.
|
| [9] |
Bernheim AM,Connolly HM,Pellikka PA.Carcinoid heart disease in patients without hepatic metastases.Am J Cardiol, 2007, 99(2): 292-294.
|
| [10] |
Eriksson B,Oberg K,Stridsberg M. Tumor markers in neuroendocrine tumors.Digestion, 2000, 62(1): 33-38.
|
| [11] |
杨晓鸥,钱家鸣,李景南. 血浆嗜铬粒蛋白A对胃肠胰腺内分泌肿瘤的诊断价值. 胃肠病学, 2008, 13: 205-208.
|
| [12] |
Klby L,Bernhardt P,Swrd C, et al.Chromogranin A as a determinant of midgut carcinoid tumour volume.Regul Pept, 2004, 120(1-3): 269-273.
|
| [13] |
Campana D,Nori F,Piscitelli L, et al.Chromogranin A：is it a useful marker of neuroendocrine tumors? .Clin Oncol, 2007, 25(15): 1967-1973.
|
| [14] |
Oberg K. Biochemical diagnosis of neuroendocrine GEP tumor.Yale J Biol Med, 1997, 70(5-6): 501-508.
|
| [15] |
Ardill JE,Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.Endocr Relat Cancer, 2003, 10(4): 459-462.
|
| [16] |
Welin S,Stridsberg M,Cunningham J, et al.Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors.Neuroendocrinology, 2009, 89(3): 302-307.
|
| [17] |
Korse CM,Taal BG,de Groot CA, et al.Chromogranin-A and N-terminal pro-brain natriuretic peptide：an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.J Clin Oncol, 2009, 27(26): 4293-4299.
|
| [18] |
Vinik AI,Woltering EA,Warner RR, et al.NANENS consensus guidelines for the diagnosis of neuroendocrine tumor.Pancreas, 2010, 39(6): 713-734.
|
| [19] |
O'Dorisio TM,Krutzik SR,Woltering EA, et al.Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.Pancreas, 2010, 39(5): 611-616.
|
| [20] |
Stridsberg M,Eriksson B,Fellstrom B, et al.Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept, 2007, 139(1-3): 80-83.
|
| [21] |
Tellez MR,Mamikunian G,O'Dorisio TM, et al.A Single Fasting Plasma 5-HIAA value vorrelates eith 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors(NENs). Pancreas, 2013, 42(3): 405-410.
|
| [22] |
Eriksson B,Oberg K,Stridsberg M. Tumor markers in neuroendocrine tumors.Digestion, 2000, 62(1): 33-38.
|
| [23] |
Norheim I,Oberg K,Theodorsson-Norheim E, et al.Malignant carcinoid tumors.An analysis of 103 patients with regard to tumor localization, hormone production, and survival.Ann Surg, 1987, 206(7): 115-125.
|
| [24] |
Rockall AG,Reznek RH.Imaging of neuroendocrine tumours(CT/MR/US). Best Pract Res Clin Endocrinol Metab, 2007, 21(l): 43-68.
|
| [25] |
Oberg K,Eriksson B. Nuclear medicine in the detection, staging, and treatment of gastrointestinal carcinoid tumors.Best Pract Res Clin Endocrinol Metab, 2005, 19(2): 265-276.
|
| [26] |
Furata N,Kiyota H,Yoshigoe F, et al.Diagnosis of pheochromocytoma using [123I]-compared with [13 H]-metaiodobenzylguanidine scintigraphy.Int J Urol, 1999, 6(3): 119-124.
|
| [27] |
Meyer-Rochow GY,Schembri GP,Benn DE, et al.The utility of metaiodobenzyl guanidine single photon emission computed tomography/computed tomography(MIBG SPECT/CT)for the diagnosis of pheochromocytoma.Ann Surg Oncol, 2010, 17(2): 392-400.
|
| [28] |
Rozovsky K,Koplewitz BZ,Krausz Y, et al.Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma.AJRAm J Roentgenol, 2008, 190(4): 1085-1090.
|
| [29] |
Hofland LJ,Lamberts SW.Somatostatin receptor subtype expression in human tumors.Ann Oncol, 2001, 12(2): 31-36.
|
| [30] |
Illouz F,Sadoul JL,Rohmer V. Somatostatin receptor-based imaging and therapy of digestive endocrine tumors.Ann Endocrinol(Paris), 2010, 71(1): 3-12.
|
| [31] |
Kaltsas G,Rockall A,Papadogias D, et al.Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.Eur J Endocrinol, 2004, 151(1): 15-27.
|
| [32] |
Bushnell DL,Menda Y,Madsen MT, et al.99mTc Depreotide tumour uptake in patients with non-Hodgkin's lymphoma.Nucl Med Commun, 2004, 25(8): 839-843.
|
| [33] |
Kjell Oberg.Neuroendocrine tumors(NETs)：historical overview and epidemiology.Tumori, 2010, 96(5): 797-801.
|
| [34] |
Solcia E,Kloppel G,Sobin LH.Histologic typing of endocrine tumours.WHOinternational histological classification of tumours.Heidelberg: Springer Verlag, 2000.
|
| [35] |
Bosman FT,Carneiro F,Hruban RH, et al.Pathology and genetics of tumours of the digestive system.Lyon：IARC press, 2010: 13-14.
|
| [36] |
Sobin LH,Gospodarowicz MK,Wittekind C, et al.TNM Classification of Malignant Tumors.Oxford：Wiley-Blackwell, 2009.
|
| [37] |
中国胃肠胰神经内分泌肿瘤病理专家组. 中国胃肠胰神经内分泌肿瘤病理学诊断共识意见. 中华病理学杂志, 2011, 40(2): 257-262.
|
| [38] |
Scoazec JY,Couvelard A. The new WHO classification of digestive neuroendocrine tumors.Ann Pathol, 2011, 31(3): 88-92.
|
| [39] |
周晓军,樊祥山. 解读2010年消化系统肿瘤WHO分类(I). 临床与实验病理学杂志, 2011, 27(4): 341-346.
|
| [40] |
Foltyn W, Zajcki W,Marek B, et al.The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.Endokrynol Pol, 2012, 63(5): 362-366.
|
| [41] |
Garcia-Carbonero R,Capdevila J,Crespo-Herrero G, et al.Gas-t-rointestinal tumors：incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors(GEP-NENs)：results from the national cancer registry of Spain(RGETNE). Ann Onc, 2010, 21(9): 1794-1803.
|
| [42] |
Hodul PJ,Strosberg JR,Kvols LK.Aggressive surgical resection in the management of pancreatic neuroendocrinetumors：when is it indicated？Cancer Control, 2008, 15(3): 314-321.
|
| [43] |
Soga J. Carcinoids of the colon and ileocecal region：a statistical evaluation of 363 cases collected from the literature.J Exp Clin Cancer Res, 1998, 17(2): 139-148.
|
| [44] |
Modlin IM,Latich I,Kidd M, et al.Therapeutic options for gastrointestinal carcinoids.Clin Gastroenterol Hepatol, 2006, 4(5): 526-547.
|
| [45] |
Brenner B,Tang LH,Shia J, et al.Small cell carcinomas of the gastrointestinal tract：clinicopathological features and treatment approach.Semin Oncol, 2007, 34(1): 43-50.
|
| [46] |
Fendrich V,Bartsch DK.Surgical treatment of gastrointestinal neuroendocrine tumors.Langenbecks Arch Surg, 2011, 396(3): 299-311.
|
| [47] |
Plockinger U,Rindi G,Arnold R, et al.Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours.A consensus statement on behalf of the European Neuroendocrine Tumour Society(ENETS). Neuroendocrinology, 2004, 80(4): 394-424.
|
| [48] |
McEntee GP,Nagorney DM,Kvols LK, et al.Cytoreductive hepaticsurgery for neuroendocrine tumors.Surgery, 1990, 108(6): 1091-1096.
|
| [49] |
Oberg K,Jelic S. Neuroendocrine gastroenteropancreatic tumors：ESMO clinical recommendation for diagnosis, treatment and follow-up.Ann Oncol, 2009, 20(5): 150-153.
|
| [50] |
Oberg K,Kvols L,Caplin M, et al.Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of thegastroenteropancreatic system.Ann Oncol, 2004, 15: 966-973.
|
| [51] |
Oberg K,Akerström G,Rindi G, et al.Neuroendocrine gastroenteropancreatic tumours：ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol, 2010, 21(5): 223-227.
|
| [52] |
Swrd C,Johanson V,Nieveen van Dijkum E, et al.Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome.Surg, 2009, 96(5): 517-521.
|
| [53] |
Gupta S,Johnson MM,Murthy R, et al.Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors：variables affecting response rates and survival.Cancer, 2005, 104(1): 1590-1602.
|
| [54] |
Salavati A,Prasad V,Schneider CP, et al.Peptide receptor radionuclide therapy of Merkel cell carcinoma using(177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy：a potential novel treatment based on molecular pathology.Ann Nucl Med, 2012, 26(3): 365-369.
|
| [55] |
Yao JC,Hassan M,Phan A, et al.One hundred years after" carcinoid" ：epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 casesin the United States.J Clin Oncol, 2008, 26: 3063-3072.
|
| [56] |
Pape UF,Jann H,Muller-Nordhorn J, et al.Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.Cancer, 2008, 113(2): 256-265.
|
| [57] |
Yao JC,Lombard-Bohas C,Baudin E, et al.Daily oral everolimus activity inpatients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy：a phase II trial.J Clin Oncol, 2010, 28: 69-76.
|